| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
The primary targets of Rutarin are not well-defined in the context of pharmacological activity. As a coumarin derivative, it is known to modulate various molecular pathways involved in oxidative stress and inflammation. Rutarin inhibits Plasmodium falciparum with an IC50 of 88 μg/mL, indicating antimalarial activity. It also inhibits the fungus Coniophora cerebella. The compound's mechanism of action and its specific molecular targets are not extensively characterized in the available literature.
|
|---|---|
| ln Vitro |
Rutarin demonstrates in vitro antimalarial activity against Plasmodium falciparum with an IC50 of 88 μg/mL. It also exhibits antifungal activity against Coniophora cerebella. The compound's antioxidant, anti-inflammatory, and anticancer activities have been reported, but quantitative data such as IC50 or EC50 values for these activities are not extensively detailed in the available literature. Rutarin is primarily used as a research tool to study the pharmacological properties of coumarin derivatives.
|
| ln Vivo |
In vivo data for Rutarin are not extensively reported in the available literature. As a natural product with antioxidant, anti-inflammatory, and anticancer activities, the compound has potential for in vivo applications in models of chronic diseases. However, specific in vivo efficacy data, including animal models, dosing regimens, and pharmacokinetic-pharmacodynamic relationships, are not detailed in the available sources. The compound is classified as a research-use-only chemical.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Rutarin are not typically performed, as the compound's molecular targets are not well-defined. The compound's antimalarial activity is assessed in assays measuring the inhibition of Plasmodium falciparum growth in culture. Antifungal activity is assessed in assays measuring the inhibition of fungal growth. These assays are used to characterize the compound's biological activity.
|
| Cell Assay |
Cellular assays for Rutarin are performed in Plasmodium falciparum cultures to assess its antimalarial activity. Parasites are cultured in the presence of varying concentrations of Rutarin, and parasite growth is measured to determine the IC50. Antifungal assays are performed using Coniophora cerebella cultures. The compound's antioxidant, anti-inflammatory, and anticancer activities may be assessed in relevant cell-based models, but specific protocols are not detailed in the available literature.
|
| Animal Protocol |
In vivo animal studies with Rutarin are not extensively documented in the available literature. Based on its reported biological activities, potential in vivo models could include models of malaria, fungal infections, or chronic diseases such as cancer and cardiovascular disorders. However, specific protocols are not detailed in the available sources. The compound is intended for laboratory research use only.
|
| ADME/Pharmacokinetics |
Rutarin has a molecular weight of 424.40 and a molecular formula of C20H24O10. It is a coumarin glycoside that exists as a solid and is slightly soluble in water. The compound is stable when stored at -20°C. However, detailed pharmacokinetic parameters such as absorption, distribution, metabolism, excretion, half-life, and bioavailability are not available in the literature for this natural product.
|
| Toxicity/Toxicokinetics |
Rutarin has been studied for its antioxidant, anti-inflammatory, and anticancer activities, suggesting a potential for therapeutic applications. However, comprehensive toxicology data for this compound are not extensively reported. The compound is classified as a research-use-only chemical and is not intended for human consumption. Specific toxicological data, including acute toxicity, genotoxicity, and target organ effects, are not reported in the available literature.
|
| References | |
| Additional Infomation |
Rutarin is a monosaccharide derivative with the structure β-D-glucopyranose, where the hydroxyl group at position 1 is replaced by [(2S)-2-(2-hydroxypropyl-2-yl)-7-oxo-2,3-dihydro-7H-furano[3,2-g][1]benzopyran-9-yl]oxy. It is a natural product found in various plants, including ruta graveolens and citrus (Citropsis articulata). Rutarin is used as a plant metabolite, an antimalarial drug, and an antibacterial agent. It is a β-D-glucoside, a monosaccharide derivative, and a member of the psoralen class of compounds. Rutarin has been reported to exist in acacia (Atalantia racemosa), seseli grandivittatum, and ruta graveolens, with relevant data reported.
Rutarin is a research-grade natural product not approved for clinical use. Its primary applications are in natural product pharmacology and drug discovery research. The compound is used to study the pharmacological properties of coumarin derivatives and to investigate their potential for the treatment of chronic diseases such as cardiovascular disorders, neurodegenerative diseases, and cancer. Its antimalarial and antifungal activities also make it of interest for infectious disease research. |
| Molecular Formula |
C20H24O10
|
|---|---|
| Molecular Weight |
424.398567199707
|
| Exact Mass |
424.136
|
| CAS # |
20320-81-4
|
| PubChem CID |
442149
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
726.5±60.0 °C at 760 mmHg
|
| Flash Point |
258.4±26.4 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.656
|
| LogP |
-1.84
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
681
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(C)([C@@H]1CC2=C(O1)C(=C3C(=C2)C=CC(=O)O3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
JWWFVRMFYKPZNE-VVIWCBLHSA-N
|
| InChi Code |
InChI=1S/C20H24O10/c1-20(2,26)11-6-9-5-8-3-4-12(22)29-16(8)18(17(9)28-11)30-19-15(25)14(24)13(23)10(7-21)27-19/h3-5,10-11,13-15,19,21,23-26H,6-7H2,1-2H3/t10-,11+,13-,14+,15-,19+/m1/s1
|
| Chemical Name |
(2S)-2-(2-hydroxypropan-2-yl)-9-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrofuro[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3563 mL | 11.7813 mL | 23.5627 mL | |
| 5 mM | 0.4713 mL | 2.3563 mL | 4.7125 mL | |
| 10 mM | 0.2356 mL | 1.1781 mL | 2.3563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
